News
BerGenBio to Present Company Update at DNB Nordic Healthcare Conference
BerGenBio Appoints Olav Hellebø as CEO
BerGenBio Third Quarter Results 2024
BerGenBio ASA: Invitation to third quarter 2024 results webcast
CEO Martin Olin steps down
BerGenBio ASA: Minutes from Extraordinary General Meeting
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference